| Discovery and clinical introduction of first-in-class imipridone ONC201 JE Allen, CLB Kline, VV Prabhu, J Wagner, J Ishizawa, N Madhukar, ... Oncotarget 7 (45), 74380, 2016 | 163 | 2016 |
| ONC201 and imipridones: Anti-cancer compounds with clinical efficacy VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff, J Ray, A Jhaveri, ... Neoplasia 22 (12), 725-744, 2020 | 147 | 2020 |
| Role of dopamine receptors in the anticancer activity of ONC201 CLB Kline, MD Ralff, AR Lulla, JM Wagner, PH Abbosh, DT Dicker, ... Neoplasia 20 (1), 80-91, 2018 | 123 | 2018 |
| Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment J Wagner, CL Kline, L Zhou, KS Campbell, AW MacFarlane, AJ Olszanski, ... The Journal of clinical investigation 128 (6), 2325-2338, 2018 | 78 | 2018 |
| Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 J Wagner, CL Kline, MD Ralff, A Lev, A Lulla, L Zhou, GL Olson, ... Cell cycle 16 (19), 1790-1799, 2017 | 76 | 2017 |
| ONC201 demonstrates antitumor effects in both triple-negative and non–triple-negative breast cancers through TRAIL-Dependent and TRAIL-independent mechanisms MD Ralff, CLB Kline, OC Küçükkase, J Wagner, B Lim, DT Dicker, ... Molecular cancer therapeutics 16 (7), 1290-1298, 2017 | 53 | 2017 |
| ONC201: a new treatment option being tested clinically for recurrent glioblastoma MD Ralff, AR Lulla, J Wagner, WS El-Deiry Translational cancer research 6 (Suppl 7), S1239, 2017 | 51 | 2017 |
| Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP A Lev, AR Lulla, J Wagner, MD Ralff, JB Kiehl, Y Zhou, CH Benes, ... Oncotarget 8 (47), 81776, 2017 | 49 | 2017 |
| Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors VV Prabhu, AR Lulla, NS Madhukar, MD Ralff, D Zhao, CLB Kline, ... PLoS One 12 (8), e0180541, 2017 | 44 | 2017 |
| TRAIL pathway targeting therapeutics MD Ralff, WS El-Deiry Expert review of precision medicine and drug development 3 (3), 197-204, 2018 | 41 | 2018 |
| ONC201 targets AR and AR-V7 signaling, reduces PSA, and synergizes with everolimus in prostate cancer A Lev, AR Lulla, BC Ross, MD Ralff, PB Makhov, DT Dicker, WS El-Deiry Molecular Cancer Research 16 (5), 754-766, 2018 | 26 | 2018 |
| TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic MD Ralff, A Jhaveri, JE Ray, L Zhou, A Lev, KS Campbell, DT Dicker, ... Oncotarget 11 (42), 3753, 2020 | 24 | 2020 |
| Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo AV Jhaveri, L Zhou, MD Ralff, YS Lee, A Navaraj, BA Carneiro, H Safran, ... Cancer Biology & Therapy 22 (10-12), 607-618, 2021 | 17 | 2021 |
| Positive psychological well‐being: A novel concept for improving symptoms, quality of life, and health behaviors in irritable bowel syndrome EN Madva, LE Harnedy, RM Longley, A Rojas Amaris, C Castillo, ... Neurogastroenterology & Motility 35 (4), e14531, 2023 | 13 | 2023 |
| Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo JE Ray, MD Ralff, A Jhaveri, L Zhou, DT Dicker, EA Ross, WS El-Deiry Cancer Biology & Therapy 22 (10-12), 554-563, 2021 | 13 | 2021 |
| miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells AR Lulla, Y Zhou, MD Ralff, A Lev, DT Dicker, WS El-Deiry American Journal of Cancer Research 12 (1), 315, 2022 | 2 | 2022 |
| From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer‐selective Pathways CLB Kline, J Wagner, A Lulla, MD Ralff, A Lev, L Zhou, VV Prabhu, ... Early Drug Development: Bringing a Preclinical Candidate to the Clinic 2 …, 2018 | 1 | 2018 |
